Kenvue Inc.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.
Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now
Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.
Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead
KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?
Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
hould You Buy Kenvue Inc. (KVUE)’s Shares?
Kenvue Inc. (NYSE:KVUE) is one of the 10 Best Stocks to Buy According to Billionaire Glenn Dubin’s Highbridge Capital. Consumer health company Kenvue Inc. (NYSE:KVUE)’s shares are down by 8.8% over the past year and are up by 10% year-to-date. Several analysts have discussed the firm in 2026. On April 15th, Citi cut the share […]
Congressional Trades in $KVUE
Insider Trades (Form 4)
Smith Jeffrey C
Key People
Smith Jeffrey C
Director
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro